产品名称：Human CCR4 Antibody (Mogamulizumab, Research Use)
产品编号：NBR-0120
针对靶点：CCR4
抗体药商品名：Mogamulizumab
抗体药描述：Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. 产品外观：Transparent Liquid
分子量：~150kDa
CAS：N/A
溶解度：Water; PBS, TBS Buffer等
表达系统：CHO Expressed
抗体亚型：Ab. Isotype - IgG

  Gene Name: CCR4
Synonyms: CC-CKR-4; CMKBR4; K5-5; ChemR13; CD194; CKR4
Target Description: CCR4 (C-C Motif Chemokine Receptor 4) is a Protein Coding gene. Diseases associated with CCR4 include Mycosis Fungoides and Peripheral T-Cell Lymphoma. Among its related pathways are Class A/1 (Rhodopsin-like receptors) and GPCR downstream signalling. Gene Ontology (GO) annotations related to this gene include G protein-coupled receptor activity and C-C chemokine receptor activity. An important paralog of this gene is CCR1.
Ensembl: ENSG00000183813
Uniprot: P51679